Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fazirsiran in Alpha-1 Antitrypsin Deficiency Associated Liver Disease
NCT03946449Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Apr 2022
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of fazirsiran in alpha-1 antitrypsin deficiency (AATD), sponsored by Arrowhead Pharmaceuticals. Started Oct 2019; status: completed.
02
Drugs
fazirsiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03946449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946449.